Skip to main content
Have a personal or library account? Click to login
Plasma sICAM-1 correlates with tumor volume before primary radiochemotherapy of head and neck squamous cell carcinoma patients Cover

Plasma sICAM-1 correlates with tumor volume before primary radiochemotherapy of head and neck squamous cell carcinoma patients

Radiology and Oncology
Volume 56 (2022): Issue 4 (December 2022)
By: Kerstin Clasen,  Stefan Welz,  Heidrun Faltin,  Daniel Zips and  Franziska Eckert  
Open Access
|Dec 2022
Figures & tables

Figures & Tables

Figure 1

Plasma of three patients before and at end of radiochemotherapy for head and neck squamous cell carcinoma were analyzed with a human cytokine array. Of the tested cytokines, only six were present in detectable concentrations (Ccl5, Complement Component, SDF1, sICAM-1, MIF and SerpinE1). sICAM-1 was the only cytokine with a significant difference between the tested time points decreasing after treatment. sICAM-1 abundance showed moderate and strong correlations with SDF1 and SerpinE1, respectively.

Figure 2

Blood samples were taken weekly during radiochemotherapy and at every follow-up visit of the patients. In total, 86 samples were evaluated at the different time points as shown in the table for every single patient included in the study (A). sICAM-1 concentrations measured by ELISA in plasma samples of 11 patients differed significantly between patients. Over the course of treatment and compared intraindividually before and after treatment sICAM-1 concentrations did not show significant changes (B). Initial sICAM-1 concentrations showed a moderate negative correlation with relative sICAM-1 levels at the end of treatment (C).

Figure 3

Kaplan Meier analysis of disease-free survival stratified by median initial sICAM-1 concentration showed that the two patients with early recurrence in the first year after treatment were in the group with high sICAM-1 levels. Disease-free survival in the small patient cohort did not differ significantly for high and low sICAM-1 concentrations.

Figure 4

sICAM-1 levels at time points with manifest infections showed a tendency to higher concentrations compared to all other time points, however, without statistical significance (A). No difference in sICAM-1 concentrations was observed comparing time points with different documented Radiation Therapy Oncology Group (RTOG) toxicity grades (B).

Figure 5

After exclusion of one patient with a large, mostly necrotic lymph node metastasis, initial pretherapeutic sICAM-1 levels showed moderate positive correlations with primary tumor volumes (A) and volumes of lymph node metastases (B) contoured for radiotherapy planning and a strong correlation with the sum of these volumes (gross tumor volume [GTV] hull, (C)) indicating the total tumor burden of the patient at the time point of initiation of radiotherapy.
DOI: https://doi.org/10.2478/raon-2022-0043 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 501 - 507
Submitted on: Aug 31, 2022
Accepted on: Sep 29, 2022
Published on: Dec 13, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
head and neck cancer,
biomarker,
radiotherapy,
tumor volume,
gross tumor volume,
sICAM-1
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2022 Kerstin Clasen, Stefan Welz, Heidrun Faltin, Daniel Zips, Franziska Eckert, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 56 (2022): Issue 4 (December 2022)
Previous article
Next article